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THE incidence of anaplastic carcinoma of the nasopharynx in hospital patients
in Kenya is high (11 %), relative to admissions for malignant disease of other sites
(Clifford, 1961; Clifford and Beecher, 1964). Surgery has little or no place in the
management of this condition (Lederman, 1961) and, as radiotherapy is not yet
available in East Africa, treatment depends on cancer chemotherapy. Untreated,
the late stages ofthis disease can cause acute pain and severe misery to the patient
(Fig. 1 and 2), the majority of whom arrive in hospital when the disease is far
advanced.
Initially palliation with nitrogen mustard (HN2) was attempted, using the
recommended pharmacopoeial dose of 0 1 mg./kg. daily for 5 days, but experience
showed that tumour response was proportional to the dose administered, and in
the majority of these patients, little, if any, symptomatic relief was achieved
using this dosage. Cancer chemotherapy is suitable only for hospital in-patients
in Kenya. The prolonged administration of cytotoxic drugs to out-patients,
with frequent haematological examinations, is neither safe, or satisfactory under
conditions in this country, and consequently efforts have been made to achieve
the maximal therapeutic effect within the period of time that the patient resides
in the hospital. Even using larger doses of HN2, 2.0 mg./kg., with autologous
bone marrow infusions to compensate for marrow depression, useful tumour
regression was limited. Higher doses, 2 5 mg./kg. caused death due to septicaemia
secondary to gastrointestinal toxicity, before the marrow graft had fully developed
(Clifford, Clift and Duff, 1961).
As HN2 is active in the circulation for less than ten minutes, Miller and
Lawrence (1961) were able to protect the pelvic bone marrow by temporarily
occluding the abdominal aorta. It was found possible to effectively occlude the
abdominal aorta distal to the renal arteries for short periods of time, by tightly
applying an Esmarch's bandage, over small sandbags, placed on the lower abdomen
in a fully relaxed patient (Duff, Dennis, Clift, Clifford and Oettgen, 1961). Studies
indicated that the circulating blood volume was reduced to approximately one
half by an occlusion applied at this site, so that the tumour dose to the upper half
of the body of a drug calculated on a whole bodyweight basis was almost doubled.
To reduce the risk of cerebral toxicity the total dose of mustard was fractionated.
Occluding the abdominal aorta with a Kidde tourniquet and a 20 cm. Baum cuff
(Fig. 3), inflated to a pressure of 200 mm. Hg from a Medican cylinder (compressed
di-chloro-difluoromethane) was subsequently found to have technical advantages52 PETER CLIFFORD, B. V. BHARDWAJ AND L. R. WHITTAKER
(Clifford, Oettgen, Beecher, Brown, Harries and Lawes, 1963). Serial haemato-
logical examinations and sternal and iliac marrow aspiration biopsies have con-
firmed that this method effectively protects the pelvic marrow depots and elimin-
ates the risk of severe marrow depression. The abdominal aortic occlusion
(A.A.O.) must be maintained until the agent is no longer active in the circulating
blood. Thirty-eight patients with anaplastic carcinoma of the nasopharynx
were given 2*5 mg./kg. HN2, fractionated as *8, *8 and *9 mg./kg. Thirty-one
patients had effective palliation and twenty-eight were discharged clinically and
histologically free of disease, the average period of remission of symptoms being
4-5 months (but see Table IV, Cases 1, 2 and 3). Anaesthetic details, the method
of occlusion, the complications and results have been described (Clifford et ai.,
1963; Clifford, 1964). Increasing the total dose to 3.0 mg./kg. produced fatal
cerebral signs in the majority ofpatients. Using this method to protect the pelvic
marrow deposits, attempts to improve results have been directed along two lines:
(1) By using a cancer chemnotherapeutic agent which might be less toxic: (a)
Chloramine mustard, a nitrogen mustard metabolite (Hunt and Phillips, 1949)
was used in fractionated doses varying from 1.6 mg./kg. to 3 0 mg./'kg. total dose.
This compound was found to be more toxic and clinically less effective than
nitrogen mustard. Of fourteen patients with anaplastic carcinoma of the naso-
pharynx treated with this drug, only three had effective palliation and two others
died from cerebral toxicity (Oettgen, Clifford, Beecher and Gillmore, 1964). (b)
Dimethyl AMyleran, one of the methane sulfonoxy group (Timmis and Hudson,
1958) was used in fractionated doses to a total of 2X0-5X3 mg./kg. A one-hour
period of abdominal aortic occlusion was necessary to allow fixation of the drug
and protect the pelvic bone marrow. Twelve patients with anaplastic carcinoma
of the post nasal space were treated with this agent ; effective palliation was
achieved in seven, but only one (total dose 5-3 mg./kg.) was discharged from
hospital histologically free ofdisease. Her remission ofsymptoms lasted 5 months
and she died of the disease three months later. This drug did not produce signs
of cerebral toxicity, but bucco-labial mucositis and conjunctivitis were usually
severe, occasionally progressing to ulceration. These cases have been reported in
detail (Clifford, Clift, Khan and Timmis, 1964).
(2) By reducing the amount of the cytotoxic agent reaching the brain: Neither
chloramine mustard nor dimethyl Myleran produced a clinical response comparable
to that obtained using HN2. The factors limiting the dosage of HN2 appeared
to be cerebral toxicity. To overcome this barrier the amount ofHN2 reaching the
brain was reduced by clamping both internal carotids under hypothermia. The
patient's temperature was reduced to 310 C., active cooling was then stopped but a
further fall to 300 C.-290 C. usually occurred. Both internal carotid arteries
were exposed and clamps which could be closed quickly were applied. Catheters
were inserted into the right atrium through the right internal jugular vein. The
Kidde abdominal tourniquet was then inflated, both internal carotid arteries were
clamped and immediately the full dose of freshly prepared HN2 solution was
injected into the right atrium. This procedure was carried out under constant
electrocardiograph control. The rapid injection of a large dose of HN2 into the
right atrium produced little if any alteration in the cardiovascular system. Pre
and post occlusion transaminase values were unaltered. Table I gives details of
the procedure, dosage and response in six patients (Cases 1-6), all with advanced
disease, who were treated in this manner. Five patients (Cases 1-5) had obviousNITROGEN MUSTARD THERAPY IN NASOPHARYNGEAL CARCINOMA
tumour regression, noted some days after the occlusion. Case 1 remained without
evidence of disease for over two years and Case 3 was discharged clinically and
histologically free of disease but died with a recurrence eleven months later.
Case 2 subsequently died from lymphosarcoma of the heart and mediastinum.
Case 5, who showed little evidence of toxicity after this method of therapy,
subsequently died with cerebral signs following the administration of 2.0 mg./kg.
chloramine mustard with occlusion. Though Case 3 had post occlusion epileptic-
form convulsions, there were no neurological sequelae nor evidence of intellectual
impairment in this case or in the three others (Cases 1, 2 and 5) who survived.
Two cases (4, 6) died with cerebral signs. The pattern of cerebral toxicity in
these patients was similar to that noted in some patients treated with fractionated
doses of HN2 and simple A.A.O., i.e. tremors, disorientation convulsions,
unconsciousness and death. The brains of these two patients and from Case 5
were removed shortly after death and have been examined by Dr. David Oppen-
heimer at the Department of Neuropathology, Radcliffe Infirmary, Oxford, whose
report is included in TableI. Table shows the clinical and therapeutic details
of nine other patients who died while under treatment, and whose brains have
also been examined by Oppenheimer. As a result of the neuropathological reports
on Cases 4, 5 and 6 (TableI), and Reports No. 4, 5, 7, 8, 10 and (TableII),
two patients were heparinized before and for 24 hours after A.A.O. To reduce as
far as possible the amount of nitrogen mustard reaching the brain both vertebral
and internal carotid arteries were occluded for a six minute period. In both of
these patients internal and external haemorrhage was severe, and in both the
immediate cause of death was probably cardiac failure due to large mediastinal
haematoma formation. Details relating to these patients are shown in Table III.
Rationale for admninistering heparin
One of the cases (5) listed on Table Iand five of the patients (4, 5, 7, 10 and 11)
reported on Table were treated with chloramine mustard. One patient (Report
8. Table II) had intra arterial Epodyl (triethylene glycol diglycidyl ether). The
clinical signs of cerebral toxicity were no different in these patients from those
noted, following HN2 and simple A.A.O. or the more complex procedure outlined
oIn Tables I and III. Symptoms relating to auditory nerve damage, as described
by Millerand Lawrence (1961) have not been noted, but one case of optic nerve
damage occurred using chloramine mustard. As will be seen from Tables I and
examination of the brains of those patients who died with cerebral signs, showed
cerebrovascular lesions, usually thrombotic. The effect of HN2 on blood clotting
is not known (Hanratty, 1963, personal communication). Cerebral signs were
not noted when dimethyl Myleran was used (Reports 6 and 12, Table II) and this
may be related to haematological toxicity affecting blood clotting. In all cases
sections were taken of the cortex, hippocampus, hypothalamus, basal ganglia,
thalamus, midbrain medulla and cerebellum. McDonald and Asano (1961)
have described changes in the brains of mice due to HN2 toxicity, but the only
parenchymatous changes noted in these cases were associated with thrombosis
.nild ischaemia. Though no specific damage to nervous tissue directly attributable
to HN2, was discovered, this does not outrule subtle
"toxic " changes in nerve
cells which can only be demonstrated with freshly fixed experimental material and
adequate controls (Oppenheimer. 1963. personal communication). As a result of
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TABLE II.-Clinical and Therapeutic Details of 9 Patients who Died while under Treatment
and whose Brains were also Examined by Dr. Oppenheimer
KEY. Ana. C. =Anaplastic carcinoma
Lym. Sa. =Lymphosarcoma
Sq. Ca. -=Squamous carcinoma
Re- Age
port and
No. Sex Disease Therapy
4 16 M. Ana. C. A.A.O. + Chloramine
P.N.S. Mustard 1-5 mg./kg.
x2
5 30 F. Lym. Sa. A.A.O. + Chloramine
Tonsil Mustard 1-0 mg./kg.
xl 1
6 35 M. Ana. C. A.A.O. + Dimethyl
P.N.S. Myleran 0-8, 0-8, 0-9
mg./kg.
7 48 M. Sq. Ca. A.A.O. + Chloramine
Tongue Mustard 0-9 mg./kg.
8 59 M. Ana. C. Epodyl as bilateral
Tongue external carotid infu-
sion 8 hours daily. (750
mg./kg. over 10 days)
9 18 M. Osteogenic Epodyl left external
Sa. carotid infusion 8 hrs
Mandible daily (750mg./kg. over
12 days).
A.A.O. + HN2 0.8,
0-8, 0-9 mg./kg.
l0 55 M. Ana. C. A.A.O. + Chloramine
P.N.S. Mustard 1-5, 1-0, 0-8
mg./kg.
11 30 M. Ana. C. A.A.O. + Chloramine
P.N.S. Mustard 1-5 & 1-0 mg./
kg.
12 40 M. Ana. C. A.A.O. + Dimethyl
P.N.S. Myleran 1-0 mg./kg.
x3
P.N.S. =Post nasal space or nasopharynx
A.A.O. =Abdominal aortic occlusion
Sa. -Sarcoma
Fatal
toxicity
symptoms
Cerebral
Cerebral
Haematological
Cerebral
Cerebral
Haemorrhage from
infected aneurysm
left ext. carotid.
Cerebral
Cerebral-Pneumo-
nary
Haematological-
Pneumonary
Neuropathology
As for Cases 4, 5, 6 Table I
As for Cases 4, 5, 6 Table I.
Brain macroscopically and microscopically
normal.
Brain macroscopically normal.
Sprinkling of ischaemic nerve cells in cerebral
and cerebellar cortex.
Early thrombosis in some veins.
Recent infarct in left superior parietal lobule,
probably arterial.
Early venous thrombosis as in Case 7.
Ischaemic changes in cerebellum.
Macroscopically and microscopically normal.
Widespread early thrombosis in veins andl
arteries
Fresh petechial haemorrhages in subthalamic
region.
Few ischaemic cells in cerebellum.
Flattened convolutions.
Gross thickening of meninges.
Dilated ventricles and aqueduct.
Appearance ofpost meningitic hydrocephalus.
Degenerative changes in dentate nuclei.
Swollen brain.
Deposit of carcinoma on the surface of the
left fusiform gyrus, with haemorrhage, tissue
necrosis and strong glial reaction.
Oedema of left temporal lobe causing hernia-
tion of the hippocampul gyrus, and some
lateral compression of the midbrain.
No signs of thrombosis, no ischaemic changes
seen.NITROGEN MUSTARD THERAPY IN NASOPHARYNGEAL CARCINOMA
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these findings it was thought that this form oftherapy would be safer ifthe patient
was heparinized before and for 24 hours after occlusion. The procedure used on
Cases 13 and 14 (Table III) was abandoned because ofthe risk ofproducing a large
mediastinal haematoma, and it was thought that by using heparin, cerebral
arterial occlusion would not be necessary and a larger dose ofHN2 could safely be
administered.
Administration of HN2, 5 mg./kg., with A.A.O. to heparinized patients
Using heparin as described, twenty-onepatientswithnasopharyngeal carcinoma
have been given 5.0 mg./kg. HN2 as 1*0 mg./kg. x 5. Details of treatment,
toxicity and response noted in these patients are outlined on Table IV.
Response.-Treatment produced marked objective and subjective improvement
in all patients treated. Large nasopharyngeal tumours and secondary neck
gland masses disappeared or were greatly reduced in size, and symptoms such as
nasal obstruction, epistaxis, headache and cervical neuralgia were relieved. Of
the twenty-one patients described, eight (Cases 2, 3, 10, 11, 14, 18, 19 and 21)
were discharged from hospital with total regression of the disease, confirmed
histologically (Fig. 4 and 5), but recurrence was evident in 2 ofthese (Cases 18 and
19) within a four month period, and Case 3 died at home, probably with disease,
nine months after his discharge from hospital. Complete clinical regression was
also noted in Case 9, who declined a proof biopsy. Marked objective and subjec-
tive response was achieved in six other patients (Cases 7, 8, 11, 15, 16 and 17)
(Fig. 6 and 7), in whom disease was still present on completion of treatment.
Four patients (Cases 2, 10, 11 and 21) are alive and well for longer than twelve
months from the date ofcommencement of cancer chemotherapy. Seven patients
(Cases 1, 4, 5, 6, 12, 13 and 20) died while in hospital. Case 4 died from acute
pulmonary tuberculosis, histologically free of cancer, sixty-one days after the
last occlusion, but the cause of death in the other six was directly related to
therapy. All six cases developed pulmonary lesions, and four of these patients
(Cases 5, 6, 12 and 20) had associated cerebral signs. Case 6 (Fig. 8) had shown
marked clinical regression of the disease after receiving 5-0 mg./kg. (Fig. 9), but
proof biopsy taken from the neck was positive. A further 4 0 mg./kg. was given
before his death, and no tumour tissue was evident on histological examination of
post mortem specimens from the nasopharynx and neck gland area. Case 20 had
total regression of his enlarged neck glands after receiving 4-0 mg./kg., but a
proofbiopsy from the nasopharynx was positive. A further 2-0 mg. was adminis-
tered and the patient died from bronchopneumonia after the last occlusion. On
post mortem examination there was no evidence of disease and specimens from
the nasopharynx and neck gland area were negative. The brains of these two
patients have also been examined by Oppenheimer, whose report was as follows:
Case 6: Brain grossly normal. Microscopically, fragments of what
appear to be recent ante-mortem thrombus seen in the basilar artery and
in some veins around the brain stem. No signs of cerebral ischaemia.
Case 20: Old traumatic scar in left middle frontal gyrus. Generalized
anoxic cell changes. Suggestion of pre-terminal infarction of parts of
left and right frontal cortex, white matter and basal ganglia. No intra-
vascular thrombi seen.
Both cases had been heparinized immediately before and for the first 24 hours after
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the four A.A.O.'s which preceded death. The cerebrovascular lesions noted by
Oppenheimer in these patients may have resulted from post occlusion hypotension.
Effects ofpost occlusion hypotension
Within the first 24 hours after the termination ofan A.A.O., a profound fall in
B.P. up to 60 mm. Hg systolic may be evident in a certain number of patients.
Gilman and Philips (1946) have described the systemic pharmacological action of
the mustard drugs, noting the parasympathomimetic and neurotoxic properties
ofthese drugs, and this may be a factor in post occlusion hypotension, though a fall
in blood pressure has not occurred in all patients treated. Hypotension has not
been marked when other agents, such as Actinomycin D or dimethyl Myleran,
were administered with A.A.O., and cerebral signs have not occurred when these
agents were used.
The manner ofocclusion may be related to the hypotension. Harries, Beecher,
Brown and Oettgen (1963) have examined the haemodynamic effects of this
procedure and suggested that post occlusion hypotension may be initially due to an
overall decrease in peripheral resistance, due to a sudden increase in the vascular
bed when the Kidde tourniquet was released. Later the release of histamine like
substances in the compressed gut and occluded lower limbs may produce a condi-
tion akin to " tourniquet shock ". Harries et al. (1963) have shown that a fall in
cardiac output and a rise in pulmonary arterial pressure occurs during occlusion.
This indicates that an increase in pulmonary peripheral resistance occurs, which
may be due to compression ofthe pulmonary vessels and a reduction in the venous
return to the heart. It is possible to speculate on the relationship between the
resultant venous stasis and pulmonary infarction, discussed below.
(a) Cerebrovascular complications were almost all confined to patients
who had post occlusion hypotension. The most common complications of
induced hypotension are those involving the brain and cerebral thrombosis
is sometimes noted (Van Bergen, Buckley, French, Dobkin, and Brown,
1954). Adriani (1961) has stated that a reduction in cerebral blood flow
occurs when the systolic blood pressure falls below 6Y mm. Hg and at this
level evidence of inadequate cerebral perfusion is manifest in the electro-
encephalogram of the unanaesthetised patient. We now consider that
post occlusion hypotension requires immediate correction, otherwise the
majority of patients in this state shortly afterwards develop cerebral signs
which usually progress to death.
(b) Pulmonary complications. Details of the method of anaesthesia
have been described (Clifford et al., 1963) and it is considered that the
pulmonary complications are not related to the repeated anaesthetics
given at the intervals noted on Table IV.
Reference has previously been made (Clifford, 1964) to the atypical
lobar pneumonia, possibly thrombotic in origin, which some of these
patients developed. Review of the radiologically evident pulmonary
complications has shown three main features invariably occurring in the
right lung. These appearances have suggested a lobar pneumonia, for
example of the right middle lobe (as in Fig. 10), or a bronchopneumonic
type of pneumonia affecting segments of the lower lobe (as in Fig. 11(a)
and (b)).
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TABLE IV.-Details of Toxicity and Response in 21 Heparinised Patients Given
KEY. Ana. C.
Epid. Ca.
P.N.S.
D1
= Anaplastic carcinoma
-= Epidermoid carcinoma
= Post nasal space or nasopharynx
= 1st day of treatment
Clinical Details
A~~ ~ ~ ~ -
P.N.S. Cranial
Age Tumour Nerve
& & Neck Involve-
No. Sex Histology Glands ment
1. 14F. +++ +++ 3,4,5
Ana. C.
Other Therapy
7
-A _
Date, Method
Total dose:
mg./kg.
5 FU by
D1 J Bilat. Ext.
to Carotid
D58 Infusion
Three courses
to toxicity
HN2 + A.A.O.
r--
A .A, _%
mg./
Day Dose kg.
D94 26 TnIARn oa lJlUU
D140
D144
D149
2. 20F. ++++
Ana. C.
3. 26M. +++
Ana. C.
4. 28 M. +
Hard
smooth
Ana. C.
+++ Nil DI
D3
D9
D92
D96
D101O
27 27
27J
30J
33
33
35
35
35
40
+++ 9, 10, 11, D1 30
12 D8 30
D20 36 J
Respon
Slight objective &
subjective improve-
ment
1.6 Discharged D173. D786
Clinically & histo- D791
logically free ofdis- D798
2.5 ease. Readmitted D880
D781 with recur- D821
rence.
D80. P.N.S. histo- D889
2-5 logically negative. D915
Neckglands + Dis- D932
charged Dlll as D950
2- 5 free of disease. Re- D972J
admitted D878 with
recurrence.
D43. No clinical or D592
2-5 histological evi- D606
dence of disease. D613
Readmitted D582 D620
with recurrence. D644
Nil 5 Dl: Epodyl 10 c.c. Clinically total re-
+ A.A.O. for 20 gression. Proof bi-
min. = 225 mg./kg. opsies D24-Neg.
D14: Repeated. D34-Neg. Dis-
charged D41.
D340
D347
D351
D354
D375
Total
Quan- mg./
Lse Dates tity kg.
28
28
27
27
26
5'o
50 5.0
40
40
38
40
40
50
47
45
42
40
5'0
5-0
5. 43 F. Nil.
Mucosal
strip
biopsy
Ana. C.
++++ Nil. Dl 39
D8 39
D15 38 r
D19 35
4.0NITROGEN MUSTARD THERAPY IN NASOPHARYNGEAL CARCINOMA
Nitrogen Mustard with Abdominal Aortic Occlusion
D6
A.A.O.
T.W.C.C.
-= 6th day of treatment, etc.
= Abdominal aortic occlusion
-= Total white cell count
HN2 as 1-0 mg./kg. x X + A.A.O. (200 mm. Hg./20 min.) + Heparin
Toxicity
Hypo-
Heparin Vomit. Diarr. Tension Pulm. Neuro. Haem. Response Remarks
5,000 U. 5 hour-
ly x 5
7,500 U. imme-
diately before
A.A.O. repeated
4 x 5 hourly.
Complete clinical
regression D825.
D827 Consolida-
tion left upper
lobe. Died D835
from severe bron-
cho-pneumonia.
7,500 U. imme-
diately before
A.A.O. repeated
4 X 5 hourly.
{As for Case 2.
As for Case 2. 1
Heparin 5000 U.
6 hourly for 24
hours.
+
+
+ -F
+
Proof biopsy
P.N.S. and neck
D1014 negative.
++
++
+
+
+
+
+
+ +-
+
+
+
+
++
++
++-
Discharged D679
clinically & histo-
logically free of
disease.
Clinically total re-
gression. Sputum
Nil. + T.B. D413.
+
±+± +±±
D21. Mental con-
fusion & digital
tremors. D23.
Drowsy. D25. Sali-
vation + + +.
D29.Incontinent&
unconscious. Died
D37 from broncho-
pneumonia.
D882. Biopsy P.N.S.
negative. Neck glands
+. Discharged D1020
without evidence of
disease.
Died at home, D953.
?recurrence. No P.M.
ReadmittedD329with
large neck glands and
P.N.S. tumour. Bi-
opsy +. Died from
Pulm. T.B. D436. No
Histological evidence
of tumour at P.M.
which confirmed
cause of death.
P.M. No evidence of
tumour. P.N.S. and
neck histologically
negative.
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Clinical Details
P.N.S. Cranial
Age Tumour Nerve
& & Neck Involve-
No. Sex Histology Glands ment
6. 38M. ++ ++++ Nil.
Ana. C.
7. 25 M. +++
Ana. C.
8. 26M. ++++
Ana. C.
+
++ 5
3, 4, 5, 6
Other therapy
A..
Date, Method
Total dose:
mg./kg. Response Dates
D1
D4
D18
D25
D34
D74
D81
D85
D88
D1
D17
D35
D52
D77
D1
D5
D12
D29
D36
D173-D215: Cyto- Nil. Neck mass in- D89
xan 350 mg. orally creasing. Haemato-
daily (7 mg./kg.) logical toxicity
D215. T.W.C.C.:
1000 Plat.: 150,000
Qua!i-
tity
48
46
42
41
41
48
45
45
40J
40
40
39
38
36
54
53
50
50
50
55
9. 32M. +
Epid. Ca.
10. 34M. ++
Ana. C.
11. 36 M. +++
Ana. C.
++ Nil. Blockdissection neck
glands. D1 and D2.
Melphalan 60 mg. ?
I.V. or 2-0 mg./kg. D16:
T.W.C.C.: 2000
Platelets: 800
+ + + Nil.
+ + 3, 4, 6 Surgery: left antro-
ethmoidal excision+
orbit. D262 D262-
D311: Cytoxan 300
mg. orally daily 6
mg./kg.
D311:
T.W.C.C: 1,300
Platelets: 240,000
Total
mg./
kg.
5'0
4'0
5.0
5-0
1.0
D34 57
D54 57
D65 55
D79 53
4- 0
5.0
D1
D4
D8
D15
D18
D1
D4
Dll
D15
D18
53
50
50
46
46
50
48
45
45
45NITROGEN MUSTARD THERAPY IN NASOPHARYNGEAL CARCINOMA
HN2 as 1-0 mg./kg. x X + A.A.O. (200 mm. Hg./20 min.) + Heparin
Toxicity
Heparin Vomit. Diarr.
Hypo-
Tension Pulm. Neuro. Haem.
No Heparin.
5000 U. 5 hrly
X 5
As for Case 2.
As for Case 2.
++
++
+++-
++
Neck circumfer-
ence decreased by
18 cm. on D50.
+
+
++ + +++ +++
As for Case 2.
+++
++
+
+--q
As for Case 2.
As for Case 2.
As for Case 2.
As for Case 2.
As for Case 2.
+
+
+
+
++
++
+
+
q-
++
+-q
+
+
+
q-
++
+
D98: D90-D100. Mental
T.W.C.C. confusion & dis-
1900 orientation-un-
Plat. consciousness.
7000
Proof biopsy
P.N.S. D84: Nega-
tive. Discharged
D102
D58. Proof biopsy
P.N.S. negative.
Residual lump in
neck +.
Laparotomy D90.
Haemorrhage from
torn mesentery.
D94. No clinical
evidence ofdisease.
Biopsy refused.
Total clinical re-
gression. Proof
biopsy P.N.S. D36
-negative.
Total regression
confirmed histolo-
gically D43. q-
+-
D10. Sonne dysen-
tery. Depilation D50.
Died from broncho-
pneumonia D100.
Histologically no
tumour in P.N.S.-
neck fibrous tissue
only.
Readmitted D165
with severe headache
and face pain.
Exploration showed
tumour in left cavum
trigeminale.
Patient requested dis-
charge D103. Read-
mitted D172. Dis-
charged D222, to
District Hospital on
sedatives.
D94. Patient reques-
ted discharge. Seen
in follow-up D171-
no signs of recur-
rence.
Discharged D42. Fol-
low up D441-still
without evidence of
disease.
Discharged D47. Re-
admitted with early
recurrence in left
ethmoid D250. Dis-
charged D316 on
maintenance Cyto-
xan. Follow-up D527
-still without evi-
dence of disease.
Response Remarks
t
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Clinical Details Other therapy
P.N.S. Cranial
Age Tumour Nerve Date, Method Total
& & Neck Involve- Total dose: Quan- mg./
No. Sex Histology Glands ment mg./kg. Response Dates tity kg.
12. 33M. ++--~- ---{- 10,11,12 DI O1
Ana. C. 0D7 49t 3 0
D37 49
D234 44
D248 38
D255 40 5-0
D276 40
D294 40J
13. 45 M. +++ ++-
Ana. C.
14. 50MA. +---+ ++
Ulcerating +
Ana. C.
15. 20 F. ++-++ ±++
Ana. C.
+ 2,3,4,5,
6
D115:
Actinomycin D 1.0
mg. + A.A.O. 200 Died D116.
mm. Hg. for 45 min.
Nil,
+ 3,4,6
16. 14M. +--+
Ana. C.
+- + Nil.
D172:
Actinomycin
D 1- 0mg. + A.A.O.
D1 30-
D15 28
D33 27 5- 0
D40 27
D47 26 J
D216 30
D223 30 3 3-0
D250 30 J
64
D1
D15
D25
D33
D40
D1
D5
D23
D40
D54
D1
D8
Dll
D22
D40
551
54
50 5-0
49
50J
50f
47
46 5.0
46
47J
44
43
40 50-
42
42NITROGEN MUSTARD THERAPY IN NASOPHARYNGEAL CARCINOMA
HN2 as 1-0 mg./kg. x X + A.A.O. (200 mm. Hg./20 min.) + Heparin
Toxicity
Heparin
As for Case 2.
First A.A.O.
without heparin
because of epis-
taxis. Others as
for Case 2.
As for Case 2.
As for Case 2.
{As for Case 2.
As for Case 2.
As for Case 2.
for 2.
Hypo-
Vomit. Diarr. Tension
+ +
++
+
++
++
+
+
+
++
+-
q-
+
+
+
+
++
+
Pulm. Neuro. Haem.
+
+
Response
Very marked tu-
mour regression.
No proof biopsy.
Bleeding ceased
after 1st A.A.O.
Very marked tu-
mour regression.
Died D303.
Clinically total re-
gression. Proof bi-
opsy P.N.S. D58-
positive.
Clinically total tu-
mour regression.
Proof biopsy
P.N.S. D62-
negative.
Marked regression
by D33, cranial
nerve lesions clear.
D58, no tumour in
P.N.S. mucosal
strip biopsy nega-
tive, neck glands
regressed to hard
mass of fibrous
tissue. Block dis-
section tissue his-
tologically +.
Total clinical re-
gression. Proof bi-
opsyP.N.S. D56-
negative.
++
+
+ +-
Remarks
Patient requested dis-
charge D54. Re-
admitted D227 with
severe epistaxis due
to recurrence of
P.N.S. tumour
+ ++. D257. X-ray
chest suggest Rt. low-
er lobe infarction.
P.M. Left broncho-
pneumonia. No mac-
roscopic tumrnour but
histologically sub-
mucosal disease.
Pneumonia D89-
D102. D106: Rapidly
growing neck deposit.
P.M. Very oedema-
tous & congested
lungs. Histologically
distorted tumour cells
in P.N.S.
Discharged without
evidence of disease
D68.
Discharged D76.
Satisfactory D96.
Shigella Sonne dy-
sentery D3. Dis-
charged D66.
Readmitted D168
with early recur-
rence. Biopsy +
D170.
Declined further
treatment. No clini-
cal evidence of dis-
ease at discharge
D256. Follow-up
D342: recurrence.
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Clinical Details
Age
&
No. Sex
17. 12 M.
P.N.S.
Tumour
&
Histology
+++Ana. C. Ana. C.
18. 26M. + + +
Ana. C.
Cranial
Nerve
Involve-
ment
Nil.
Other therapy
.A - ,%
Date, Method
Total dose:
mg./kg. Response Dates
D86-D176: Cyto- Tumour appears to D1
xan 200 mg. orally be controlled by D8
7 0 mg./kg. maintenance Cyto- D22
xan, to D321. D25
D36
Nil. D1
D8
D25
D40
D50
Neck
Glands
+++
++
19. 22 M. +
Epid. Ca.
20. 40M. + + + +
Ana. C.
++ + Nil.
+++ Nil.
21. 26M. ++++
Ana. C.
+ + + Nil. dimethyl Myleran +
A.A.O.
D1 48
D5 48 3.0
Dll 54
Haem. Toxicity D256
D28: T.W.C.C. D263
1,200 Platelets D267
28,000. Bucco- D284
labial ulceration D295
D17-D30. Total re-
gression of P.N.S.
tumour and neck
glands, but mucosal
strip biopsy + D61.
A third group did not suggest an inflammatory process. The appearance
was of a homogeneous opacity affecting either the area of the anterior segment of
the upper lobe or the segments of the middle lobe or the basal segments of the
lower lobe ofthe right lung (Fig. 12), which opacity did not involve the whole lobe
but tended to be peripheral with the long axis along the longest adjacent pleural
surface. The opacity became less dense as it progressed from the peripheral
pleural surface (Fig. 12). It was originally anticipated that the first two radio-
logical appearances of lobar and bronchopneumonia were purely inflammatory
66
Total
mg./
kg.
5'0
5'0
Quan-
tity
28
28
27
26
25
6) 1° 43
42r
43J
D1
D23
D29
D39
D53
54
50
48
48
47
50
50
50
45
50
50J
5.0
6.0
D1
Dll
D13
D22
D53
D67
48
46
45
50
47
5 0NITROGEN MUSTARD THERAPY IN NASOPHARYNGEAL CARCINOMA
HN2 as 1-0 mg./kg. x X + A.A.O. (200 mm. Hg./20 min.) + Heparin
Txct
Toxicity
r o- %
Heparin
As for Case 2.
As for Case 2
Vomit.
+
+
+
+
+
+
+-
Hypo-
Diarr. Tension Pulm. Neuro.
+-q-
+ ++
+
? +
(see re-
marks)
As for Case 2.
No Heparin
As for Case 2.
Asfor Case 2. + +
I+~~~q
+
D55-
D58+ +
+++ +++
+
+
+
+
+
+
+
+
Haem.
Dll:
T.W.C.C.
1400
Plat.
210,000
D29
T.W.C.C.
1600
Plat.
65,000
Response
Total clinical re-
gression D47.
Proof biopsy D82
q-.
D58. Total tumour
regression recon-
firmed histologi-
cally D121. Died
D174.
D31: Clinically total re-
T.W.C.C. gression. Proof
1950 biopsy P.N.S. D66
Plat. -negative.
65,000
Neurological signs
were lethargy
and tremors of
hands. Tumour
regression evident
by D15. Total
clinical regression
D36, but proof bi-
opsy P.N.S. +.
+ D277 Total clinical re-
T.W.C.C. gression. Proof
1,700 biopsy P.N.S.
Plat. D305-Negative.
23,000
Remarks
D47: Depilation+ +
D134. Severe head-
ache and joint pain
-general muscle
wasting.
P.M. PulmonaryT.B.
Secondary tumour
deposits in liver and
cervical glands.
P.N.S. negative.
Discharged well D72.
Mental state normal.
Readmitted D185
with recurrence.
Tracheostomy D1
after A.A.O,
closed D6. Died D76
withpneumonic signs.
P.M.: Atypical pneu-
monia- ? thrombo-
tic. No tumour tissue
evident.
Patient requested dis-
charge D64. Readmit-
ted D251. Recurrence
+. 6th cranial nerve
paresis present on re-
admission cleared
D270. Discharged
D310. Follow-up
D430: well and free of
disease.
and possibly related to aspiration, either as a result of the primary lesion of the
upperrespiratory tract or to the A.A.O. under anaesthesia. The third group could
not be explained as an inflammatory process and it was postulated that these
appearances were caused by pulmonary infarction as they corresponded to the
radiological appearances of infarction as described by Hampton and Castleman
(1940). Short (1951) has described the appearance of an infarct shadow as
consolidation, basal clouding, costophrenic shadow, linear shadow, triangular
shadow, scar and collapse. It is now suggested that some, if not many, of the
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appearances previously considered as inflammatory are not such, but are in fact
infarcts.
Of the 129 infarct shadows quoted by Short 69 were of consolidation. Lobar
consolidation in pneumonia is not uncommon in this hospital and usually involves
the whole lobe as described by Short. In the case illustrated (Fig. 10) not only
is this consolidation incomplete at the periphery, but resolution of the pneumonic
process was not synchronous throughout the whole lung but was delayed in the
proximal hilar part of the lobe (Fig. 13), though ultimately was complete (Fig. 14
and 15).
Hampton and Castleman (1940) describe how some stages ofinfarction present
histologically similar changes to those of bronchopneumonia, hence it is not
unreasonable to suppose that the appearance of bronchopneumonia could have
been due to infarction. In the first film ofthis patient (Fig. 16) there was no visible
radiological abnormality in the right cardiophrenic angle. He developed an
opacity in the right cardiophrenic angle, which opacity was not of a segmental
distribution and was peripheral (Fig. 17). Later, when healed, it left a residual
scar (Fig. 18). This is very similar to the appearance described in infarction by
Hampton and Castleman (1940), Short (1951) and Fleischner (1962), and is charac-
teristic of the findings in the series.
The site of the infarction may be of significance, for in those cases as so far
recognised it was invariably in the right lung. Short stated that in his series
two-thirds were in the right lung, and Hampton and Castleman noted that infarc-
tion occured in the right lung in 60 % of their cases.
EXPLANATION OF PLATES.
FIG. 1. 40 year old Kipsigis African presented with cervical and brachial plexus neuralgia
due to large bilateral cervical gland masses secondary to anaplastic carcinoma of naso-
pharynx.
FIG. 2. 35 year old Kikuyu with secondary cervical gland masses from an anaplastic carci-
noma of the post nasal space. His presenting symptoms were dysphagia and dyspnoea.
FIG. 3. An abdominal aortic occlusion (A.A.O.) in progress.
FIG. 4. Case 3: Table IV, before treatment.
FIG. 5.-Patient shown in Fig. 4 six days after completing treatment.
FIG. 6. Case 15: Table IV, before treatment. She had a left 3rd, 4th and 6th cranial nerve
lesion, with a large mass of left secondary neck glands from an anaplastic carcinoma of the
nasopharynx.
FIG. 7. Patients shown in Fig. 6 on completion of treatment. The left cranial nerve lesions
have resolved, and though a mucosal strip biopsy from the nasopharynx was reported free
of disease, malignant cells were evident in tissue removed subsequently from the left side of
the neck.
FIG. 8. Case 6: Table IV, before treatment.
FIG. 9. Case: Table IV, after receiving 1-0 mg./kg. HN2 x 5. The neck circumference
decreased by 54 inches.
FIG. 10. Right lateral view showing opacity of right middle lobe maximal medially.
Fig. 1la, b, Postero-anterior (a) and lateral (b) view of the chest showing apparent bron-
chopneumonic type ofinflammatory process in the right lower zone. Note increased density
of lateral right lesser fissure.
Fig. 12. Postero-anterior view of chest showing peripheral diffuse opacity with long axis
at pleural surface.
FIG. 13. Right lateral view of case shown in Fig. 10 to show residual opacity in medial part
of the middle lobe.
Fig. 14.- Laterright lateral radiograph of case shown in Fig. 10 and 13 to show complete disap-
pearance of the opacity one month later.
FIG. 15. Postero-anterior view of Fig. 14 showing residual scar.
FIG. 16.-6.12.1963: Normal right basal lung appearance preconclusion.
FIG. 17. 21. 1.1964: Diffuse opacity right cardiophrenic angle.
FIG. 18.-3.5. 1964: The residual pleural scar persists.BRITISH JOURNAL OF CANCER.
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These infarcts are not considered to be associated with pulmonary embolism
which is virtually unknown in African surgical patients. Also the signs ofpulmo-
nary artery embolism, namely oligaemia of the lung fields, with or without pleon-
aemia ofthe unobstructed lung, change in the shape and size ofthe heart, indicating
right ventricular dilatation, dilated hilar arteries, a dilated pulmonary arterial
trunk and right inflow stasis as described by Fleischner (1962), have not been
evident. Accordingly it is suggested that these appearances were due to pulmo-
nary infarction which was not due to pulmonary artery embolism.
It may well be that this pulmonary infarction is more common than has
been appreciated, for as there may be no obvious physical signs, the condition may
not be suspected, and even when suspected, radiological signs may not be present
(Short, 1951). There appears to be every justification for repeated good quality
radiography of the chest, in both postero-antero and lateral planes to identify
and localize possible infarction. It is difficult to produce serial radiographs which
allow for comparative estimations of the degree of elevation of the right diaphrag-
matic cupola, for these will depend on an accurate standard radiographic technique.
and standard phase of respiration, not always attainable with these patients.
Also it is known that many of the African patients in this hospital have basal
pulmonary adhesions, related to previous healed tubercular and inflammatory
lesions, as well as other conditions such as amoebic hepatitis (Whittaker, 1963).
Linear shadows similar to those described by Short (1951) as occurring in the lung
bases following pulmonary infarction have also been reported in amoebic hepatitis
even when there has not been proof ofpulmonary extension (Schorr and Schwartz,
1951).
The administration of heparin immediately before and for twenty hours after
occlusion has allowed the dosage of HN2 administered to be increased but, as will
be seen from Table IV, this has in no way affected the incidence of diarrhoea and
vomiting, nor lessened the need to replace potassium lost. Post occlusion hypo-
tension, pulmonary lesions and cerebral signs still are the major complications.
The pulmonary lesions are now considered to be due to infarction, possibly related
to pulmonary venous stasis. Though not entirely discounting the possibility of
HN2 producing subtle toxic changes in the brain, a common neuropathological
finding in patients who died while undergoing this treatment has been a cerebro-
vascular lesion, and this possibly may be related to post occlusion hypotension.
By routinely administering methoxamine hydrochloride immediately preceding
the release of the abdominal tourniquet it is possible to avoid post occlusion hypo-
tension and it is hoped that this will reduce the incidence ofcerebral signs in patients
undergoing this form of therapv in the future.
SUMMARY
Nasopharyngeal carcinoma is relatively common in Kenya and treatmeint
depends on cancer chemotherapy.
Nitrogen mustard has proved to be the most effective agent used to date.
Abdominal aortic occlusion effectively protects the pelvic bone marrow but the
factor limiting an increase in dosage above a fractionated dose of 2-5 mg./kg. HN2
was thought to be cerebral toxicity.
Interfering with the cerebral arterial blood supply under hypothermia before70 PETER CLIFFORD, B. V. BHARDWAJ AND L. R. WHITTAKER
the administration of HN2 did not lessen the incidence offatal cerebral complica-
tions.
Neuropathological studies on the brains of patients who died after HN2
therapy with abdominal aortic occlusion showed ante-mortem thrombi.
The administration of heparin allowed 5*0 mg./kg. HN2 to be administered to
21 patients with anaplastic carcinoma of the nasopharynx. All patients treated
had marked tumour regression. Eight were discharged from hospital without
evidence ofdisease, but the disease is known to have recurred in 3 ofthese, within
a nine months period. Seven other patients had objective and subjective relief
and 7 died while under treatment.
Neuropathological examination of the brains of 2 patients who received
5 0 mg./kg. HN2 with heparin showed cerebrovascular lesions.
Severe post occlusion hypotension either due to the parasympathomimetic
action of HN2 or due to the abdominal aortic occlusion is considered to be res-
ponsible for the cerebral signs.
Pulmonary venous stasis may lead to pulmonary infarction in patients treated
in this manner.
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